Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Trichostatin A Clear all

Conditions: Atopic Dermatitis
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 34 more

Conditions: Drug Interactions, Neoplasms
Interventions: GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more

Conditions: Food Allergy
Interventions: Omalizumab, Food Flour Allergens; Drug
Lead sponsor: Andrew Long, PharmD; Other
Eligibility: 2 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • Mountain View, California

Conditions: Metabolic Diseases
Interventions: Ultra-processed food - Picture Set Meal, Minimally Processed Food - Picture Set Meal; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Pain, Postoperative
Interventions: XaraColl, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 24
States / cities: Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 19 more

Conditions: Gastrointestinal Health
Interventions: Bacillus (Shouchella) clausii CSI08, Placebo; Dietary Supplement · Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Obesity
Interventions: glycomacropeptide (GMP); Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 90 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myelodysplastic Syndrome
Interventions: Erythropoietin, Cyclosporin A, G-CSF, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Onychomycosis of Toenail
Interventions: Trichostatin A; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Fremont, California • Denver, Colorado • New Brighton, Minnesota + 2 more

Conditions: Joint Health
Interventions: MyCondro 300mg, MyCondro 600mg; Dietary Supplement
Lead sponsor: Lesaffre International; Industry
Eligibility: 45 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Grapefruit juice, Clopidogrel 75 mg/day, Clopidogrel 300 mg; Dietary Supplement · Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Conditions: Lassa Fever
Interventions: ARN-75039 high, Intravenous ribavirin, ARN-75039 low; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Muscle Spasticity
Interventions: botulinum toxin Type A, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Downey, California • Daytona Beach, Florida

Conditions: Pain, Postoperative
Interventions: XaraColl, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 23
States / cities: Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Standard of Care; Biological · Other
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 39 more

Conditions: Coronary Artery Disease, Chest Pain
Interventions: Clopidogrel; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Seizures, Epilepsy, Seizure Disorder
Interventions: ANT recording and stimulation; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Relapsed or Refractory Hematologic Malignancies
Interventions: Trichostatin A; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Lafayette, Indiana • Hackensack, New Jersey + 1 more

Conditions: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: NRC-2694-A, Paclitaxel; Drug
Lead sponsor: NATCO Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Fullerton, California • Los Angeles, California • Boca Raton, Florida + 7 more

Conditions: Allergic Rhinitis
Interventions: Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Los Angeles, California • Mountain View, California • Walnut Creek, California + 9 more

Conditions: Knee Osteoarthritis
Interventions: CNTX-6970, Placebo; Drug
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 40 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: La Jolla, California • Sacramento, California • Gainesville, Florida + 12 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 63
States / cities: Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more

Search by objective public record fields.

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Multi OIT to Test Immune Markers After Minimum Maintenance Dose

The Effect of Processing on Food Reward

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

Establishing Effects of Bacillus Clausii Probiotic Consumption on Gastrointestinal Health and Inflammation

Glycomacropeptide and Women's Health

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

The Impact of Grapefruit Juice on the Response to Clopidogrel

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

ARN-75039 Lassa Fever Treatment in West Africa

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Thalamic Stimulation for Epilepsy Study

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)